MSD R&D INNOVATION CENTRE LIMITED
Get an alert when MSD R&D INNOVATION CENTRE LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2026-10-04 (in 5mo)
Last made up 2025-09-20
Watchouts
None on the register
Cash
—
Latest balance sheet
Net assets
£31M
+83.3% vs 2023
Employees
169
+20.7% vs 2023
Profit before tax
£5M
-6.6% vs 2023
Net assets
2-year trend · vs Health Care median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | £50,243,000 | £52,973,000 | |
| Operating profit | £5,611,000 | £415,000 | |
| Profit before tax | £5,380,000 | £5,023,000 | |
| Net profit | £3,554,000 | £2,270,000 | |
| Cash | £182,000 | — | |
| Total assets less current liabilities | £18,226,000 | £33,907,000 | |
| Net assets | £17,129,000 | £31,399,000 | |
| Equity | £17,129,000 | £31,399,000 | |
| Average employees | 140 | 169 | |
| Wages | £17,193,000 | £18,994,000 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | 11.2% | 0.8% | |
| Net margin | 7.1% | 4.3% | |
| Return on capital employed | 30.8% | 1.2% | |
| Current ratio | 1.32x | 1.47x | |
| Interest cover | 23.68x | 0.74x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- PricewaterhouseCoopers LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The Directors have prepared the financial statements on a going concern basis. Before confirming the appropriateness of the going concern basis of preparation, the Directors reviewed and considered the following: The relative strength of the MSD Group's and the Company's balance sheets in this context. The level of cash held by the Group and access to further third-party debt. On 19 December 2024 MSD R&D Innovation Centre Limited issued Merck Sharp & Dohme Research GmbH. with 1 share at a premium, as detailed in Note 15. This provided sufficient investment to sustain a net asset position and provided sufficient cash to meet the entities expenditure needs for the period ending 31 December 2024 and the forecast expenditure requirements for the period ending 31 December 2025. The directors continue to monitor the funding needs of the company and have obtained written confirmation from their immediate parent company Merck Sharp & Dohme Research GmbH., confirming support to enable the company to meet its liabilities when they fall due for a period of at least 12 months from the date of the approval of the financial statements. The company, therefore, continues to adopt the going concern basis in preparing its financial statements.”
Significant events
- “On the 10 September 2025 the Group announced that MSD Research Laboratories (MRL) intends to discontinue discovery research activities in the UK. The company also announced it no longer intends to occupy a new UK Discovery Research and Headquarters at the Belgrove House site in King's Cross.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 27 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| LUCAS, Benjamin Paul | Director | 2022-02-01 | Nov 1974 | British |
| RICHARDSON, Jill Caroline, Dr | Director | 2023-10-06 | Sep 1966 | British |
| TEMUCIN, Ebru Can | Director | 2017-06-23 | Oct 1972 | Turkish |
Show 27 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| DALBY, Marc Charles | Secretary | — | 2007-01-19 |
| DAVIES, Amy | Secretary | 2020-11-23 | 2022-05-03 |
| MCARDLE, Kevin Edward | Secretary | 2007-04-04 | 2011-06-30 |
| ROBINSKI, Richard | Secretary | 2011-06-28 | 2020-11-23 |
| ANSTICE, David Westbrook | Director | 1993-05-21 | 1994-10-04 |
| ARMITAGE, Robert | Director | 2003-09-19 | 2012-03-23 |
| ARMITAGE, Robert John | Director | 1993-12-10 | 2001-01-01 |
| BELL, Graeme | Director | 2009-06-23 | 2009-11-05 |
| BOUSFIELD, Keith | Director | 2012-03-23 | 2014-12-31 |
| CLIFFE, Christopher Frederick | Director | — | 1993-03-31 |
| HOUSON, Louise Jane | Director | 2016-09-06 | 2019-10-01 |
| JACKSON, James Russell | Director | 2001-01-01 | 2003-05-31 |
| KHANNA, Deepak Kumar | Director | 2009-11-04 | 2014-06-30 |
| KLIMCZAK, Steven Robert | Director | 1994-11-01 | 2000-10-01 |
| LAWTON, Vincent Michael | Director | — | 2006-06-28 |
| LEONARD, Melissa | Director | 2013-12-11 | 2016-10-15 |
| LEWENT, Judy Carol | Director | — | 2007-08-14 |
| LITCHFIELD, Caroline Ann | Director | 2003-06-25 | 2009-06-23 |
| MCDOWELL, Mark Andrew Charles | Director | 2009-11-04 | 2013-12-31 |
| MORAN, Michael Craig | Director | 2021-07-06 | 2023-10-06 |
| NALLY, Michael Thomas | Director | 2014-06-30 | 2016-09-30 |
| NICHOLSON, Simon | Director | 2014-12-31 | 2021-07-06 |
| PEACOCK, David | Director | 2019-10-01 | 2022-02-01 |
| POLZ, Gertraud | Director | 2016-09-06 | 2017-06-23 |
| ROUND, Christopher | Director | 2006-07-13 | 2009-11-06 |
| SPIEGEL, Francis Herman | Director | — | 1994-09-29 |
| WHITE, Katherine Elizabeth | Director | 2014-12-31 | 2016-03-18 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Merck & Co., Inc. | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-06 | Active |
Filing timeline
Last 20 of 191 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2025-12-22 | AA | accounts | Accounts with accounts type full | |
| 2025-09-22 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-12-23 | SH01 | capital | Capital allotment shares | |
| 2024-09-20 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-09-19 | AA | accounts | Accounts with accounts type full | |
| 2023-10-24 | AP01 | officers | Appoint person director company with name date | |
| 2023-10-09 | TM01 | officers | Termination director company with name termination date | |
| 2023-10-06 | AA | accounts | Accounts with accounts type full | |
| 2023-09-20 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-09-20 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-08-19 | AA | accounts | Accounts with accounts type full | |
| 2022-06-07 | PSC05 | persons-with-significant-control | Change to a person with significant control | |
| 2022-05-03 | TM02 | officers | Termination secretary company with name termination date | |
| 2022-02-02 | AP01 | officers | Appoint person director company with name date | |
| 2022-02-01 | TM01 | officers | Termination director company with name termination date | |
| 2021-10-19 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2021-09-20 | AP01 | officers | Appoint person director company with name date | |
| 2021-09-02 | AA | accounts | Accounts with accounts type full | |
| 2021-07-07 | TM01 | officers | Termination director company with name termination date | |
| 2021-01-14 | AD01 | address | Change registered office address company with date old address new address |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 2
- Capital events
- 1
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
+5.4%
£50,243,000 £52,973,000
-
Cash
—
Not reported
-
Net assets
+83.3%
£17,129,000 £31,399,000
-
Employees
+20.7%
140 169
-
Operating profit
-92.6%
£5,611,000 £415,000
-
Profit before tax
-6.6%
£5,380,000 £5,023,000
-
Wages
+10.5%
£17,193,000 £18,994,000
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers